CD8A and neoplasm: To exclude the possibility that tumor cells directly restrain CD8+ T cell–mediated immunosurveillance, we treated B16-OVA cells in the presence or absence of the UBC9 inhibitor 2-D08, followed by coculturing with OT-I CD8+ T cells.